DXCM
MERCK IS DIRT CHEAP. $11 BILLION CANCER DRUG. SALES BOOMING!We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings.
Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best!
We took a long position at $82.00 several weeks ago.
We feel the stock is worth at minimum, $150.00 all day long.
KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales.
Holding for the almost 3% Dividend and for the stock price appreciation into the future.
250,000 LONG @ $82.00
Best of Luck Everyone!
DexCom Inc - Short OpportunityAs a beginner, I'm trying to learn everything I can about investing for the long term, but also trading in the intermediate and short term. With some successes and failures now under the belt I figure I would share my next opportunity.
DexCom's recent earnings release surprised the hell out of analysts, rocketing up 27% on that day and still rising now. Hence, my next short opportunity.
A stock continually pushing a 52 week high has no reference point for resistance, therefore it's best to rely on indicators and the trusty candlestick patterns.
The volume has been dropping steadily since the earnings, pushing into overbought territory it's never seen before. At the sight of a bearish shooting star, with no increase in volume, go short!
Set yourself some reasonable profit margins and stops. Chances are it will test the $185.20 it opened at after earnings, but if you want to be more cautious utilize Fib Retracements (38.2% to 61.8%) from it's peak.
Remember, don't be greedy and lock in profits when you reach your goals.
LONG DXCM High Alpha Momentum RSI Breakout PlayDXCM flirting with new highs while RSI looks pretty constructive. This looks like it might run a bit so while it might be a nice quick momentum play there is probably a lot of long term appeal here. This also applies to AYX which I just posted.
Tandem Diabetes Care Looks Like a Good Daytrade, SwingTrade PlayStock price has not been fully established yet. Lots of uncertainty, meaning lots of opportunity for short term fluctuations. Stock just underwent reverse split. Currently a "low floater", but with real business operations, not just some cheap pump and dump scam from china or some bitcoin stock. Its a real company with real aspirations of survival. Only problem is they have much better established industry peers like Medtronics. They are still considered a player in their respective industry. Keep on watchlist, watch for movement interday, and if opportunity presents, play it.
Reason for watching, low float, recent split, and real company which is a rare thing these days in the stock market it seems like, especially if it has a low float and a real product. No MACD here people, lol. With these risky ones, flat line is a good thing after a big sell off after a reverse split, especially in a bull market. once the sellers are clearly out of the way, that's all you need to know when the stock has a low float, recent reverse split, and healthy trading volume
